INTRODUCTION:

Definition:

Artificial intelligence (AI) encompasses computer science research focused on developing intelligent systems capable of decision-making and solving intricate problems. This field utilizes advanced techniques like representation learning and deep learning. These systems aim to offer innovative solutions to historically challenging issues in AI, mimicking human-like intelligence and potentially transforming numerous industries¹.

Artificial Intelligence (AI) is a scientific discipline focused on the development of intelligent machine learning systems, primarily through sophisticated computer programs, designed to produce outcomes that mimic human cognitive processes². Recent studies detail the application of AI across various sectors, particularly in healthcare. AI technologies used in the healthcare sector include machine learning (ML), natural language processing (NLP), physical robots, and robotic process automation³. In the pharmaceutical sector, the role of AI is indispensable due to its extensive applications across various stages. AI's influence spans the entire pharmaceutical product development lifecycle, from drug discovery to product management. In drug discovery, AI technologies such as machine learning (ML), deep learning, AI-based quantitative structure-activity relationship (QSAR) technologies, QSAR-ML, virtual screening (VS), support vector machines (SVMs), deep virtual screening, deep neural networks (DNNs), and recurrent neural networks (RNNs) are employed for drug screening and design. Neural networks in AI are modeled after biological neural networks, featuring an input-output response mechanism for information processing. Artificial neural networks (ANNs) are made up of interconnected processing elements. DNNs, akin to ANNs, contain multiple layers of data-processing units, while RNNs handle data sequentially, using the output of one phase as the input for the next. SVMs are utilized for classifying and regressing input data. In pharmaceutical product development, AI aids in selecting suitable excipients, optimizing the development process, and ensuring compliance with specifications throughout the production process. In pharmaceutical product development, Model Expert Systems (MES) and Artificial Neural Networks (ANNs) are employed. AI facilitates automated and personalized manufacturing, ensuring that manufacturing errors remain within set limits. Technologies like meta-classifiers and tablet classifiers are employed to guarantee the required quality in the final product⁴.

Over the past five decades, AI in healthcare has seen remarkable evolution, resulting in significant advancements across various medical fields. The advent of machine learning (ML) and deep learning (DL) has broadened AI's applications, facilitating personalized medicine beyond traditional algorithmic approaches. AI has significantly impacted clinical decision-making, disease diagnosis, and various practices including clinical, diagnostic, rehabilitative, surgical, and predictive methods⁵. AI can analyze extensive biomedical data to uncover potential patterns, introducing fresh opportunities and challenges for pharmaceutical sciences and industries. The Alpha Fold2 system, employing AI in the 14th round of the Critical Assessment of Protein Structure Prediction (CASP14) competition, surpassed other methods in accurately predicting the three-dimensional (3D) structures of proteins⁶. Artificial intelligence (AI), often defined as the branch of computer science capable of addressing complex problems across various domains with substantial data but limited theoretical frameworks, has revolutionized medical technology⁷. AI is a rapidly advancing technology with numerous applications in both business and everyday life. The pharmaceutical industry has recently discovered innovative ways to harness this powerful technology to tackle some of its most pressing challenges. In this context, artificial intelligence refers to the use of automated algorithms for tasks traditionally requiring human intelligence. Over the past five years, the application of AI in the pharmaceutical and biotech sectors has fundamentally transformed how researchers develop new medications, treat diseases, and more⁸.

Ai in Drug Discovery and Development:

Drug discovery is well-known for being a complex and lengthy process with low success rates. On average, developing a new drug cost about $2.6 billion and usually takes over 10 years. Moreover, the success rate of advancing a drug from phase I clinical trials to market launch is challenging, typically around 10%. Over the past decade, drug discovery has been undergoing significant transformations driven by rapid advancements in computing, particularly in artificial intelligence (AI)⁹.

The integration of artificial intelligence (AI) in drug discovery is crucial. This field is primarily propelled by neural networks, including recurrent networks and deep neural networks. In recent years, numerous applications have surfaced in vehicle or performance prediction, particularly in physiochemical and ADMET products, underscoring the benefits of this method in feature relationship (QSPR) or multi-model correlation (QSAR). In de novo design, artificial intelligence guides the development of new bioactive molecules to achieve specified properties. The combination of ease of mixing with synthetic preparation enables this capability, suggesting further exploration in computer-aided medicine for future advancements¹⁰.

AI in Pharmacy Practice:

As a crucial component of the healthcare system, pharmacy practice can significantly benefit from incorporating AI technologies. It plays an essential role in healthcare by including medication management, patient counseling, and ensuring medication safety¹¹.

Pharmacy practice is essential within the healthcare system, ensuring safe and effective medication management and optimizing patient care through activities such as medication reconciliation, medication review, medication therapy management (MTM), drug information provision, patient education, adverse drug reaction (ADR) monitoring, and interprofessional collaborations¹². AI has been utilized in various studies for predicting and detecting adverse drug reactions (ADRs). One notable study conducted by Mohsen et al. integrated two disparate datasets: drug-induced gene expression profiles from the Open TG-GATEs database and adverse drug reaction (ADR) occurrence data from the FDA Adverse Events Reporting System (FAERS) database. These breakthroughs have helped transition pathology into the digital era, a field known as digital pathology¹³.

Application of AI in Pharmacy Practice:

AI is also crucial for quality improvement. By detecting patterns in medication errors and adverse drug reactions, AI can provide insights into potential systemic issues, helping to shape quality improvement strategies. For instance, Google’s AI has shown its capability to predict adverse events in hospitals and devise preventive measures, resulting in improved patient safety and overall care quality¹⁴.

Pharmacy practice-based research (PPBR) is described as "research that seeks to improve pharmacists' understanding of how practice should be directed to provide informed medication information and ensure evidence-based practice."¹⁵.

Health information technology is also used in the field of immunizations. This entails using the infrastructure to transmit immunization information to state, regional, or national registries. Such information aids in coordinating patient care for documentation, reimbursement, and quality reporting¹⁶.

Utilizing evidence-based medicine approaches in creating preferred drug lists or strategically placing drugs within a formulary structure can increase the likelihood that medications with the strongest therapeutic evidence will be selected. This aspect of pharmacy care presents exciting opportunities for graduates¹⁷.

AI In Pharmacovilance:

To mitigate the risk of harm from human adverse reactions associated with the use of medical products, both within and beyond the scope of their marketing authorizations and throughout their life cycles¹⁸. Artificial intelligence is being leveraged to enhance patient safety in both inpatient and outpatient settings¹⁹.

On a global scale, pharmacovigilance (PV) accumulates substantial daily data, posing a significant challenge in processing such extensive information. Recently, PV efforts have broadened to encompass herbals, traditional and complementary medicines, blood products, medical devices, herb vigilance, hemovigilance, and others²⁰.

Figure 1: Role of AI in Pharmacovigilance.

Disease Detection and Diagnosis:

The integration of AI into diagnostic processes, aiding healthcare professionals, holds significant potential for enhancing patient care and overall health outcomes²¹. The primary objective of disease diagnosis is to ascertain whether a patient is afflicted with a particular condition or not²². AI has been widely employed across various medical domains. It aids in clinical diagnoses of both acute conditions like acute appendicitis and chronic diseases such as Alzheimer's disease. Integrative AI, employing multiple algorithms instead of a single one, significantly enhances its capability to identify malignant cells, leading to improved diagnostic precision²³.

Treatment Planning and Personalized Medicine:

Treatment Planning and Personalized Medicine The domain of precision medicine has undergone significant advancement. Precision medicine is frequently described as a healthcare movement, which the National Research Council initially termed the development of "a New Taxonomy of human disease based on molecular biology." This represents a healthcare revolution sparked by the knowledge acquired from sequencing the human genome²⁴. When applied in healthcare, precision medicine can deliver more accurate diagnoses, anticipate disease risk before symptoms manifest, and develop tailored treatment plans that optimize safety and effectiveness. Efforts to advance precision medicine through the establishment of data repositories are not limited to the United States; the UK Biobank is one example of this global trend²⁵.

Personalized medicine employs distinct medical insights to formulate individualized approaches and treatments for detecting and addressing diseases, ultimately ensuring the well-being of individuals²⁶.

Predictive Analytics and Risk Assessment:

Disease risk assessment involves evaluating the likelihood of an individual developing specific diseases by considering factors like genetic predispositions, environmental exposures, and lifestyle choices. AI methods have been implemented to handle the different phases of clinical genomic analysis, such as variant calling, genome annotation, variant classification, and phenotype-to-genotype correlations. In the future, they might also be used for genotype-to-phenotype predictions^27. Furthermore, Ramazzotti et al. effectively predicted the prognosis for 27 out of 36 cancers by using AI to analyze various biological data types, such as RNA expression, point mutations, DNA methylation, and copy number variation omics data The Cancer Genome Atlas (TCGA) provided the data used in this analysis²⁸.

AI In Pathology:

AI techniques are becoming increasingly prevalent in pathology to perform a variety of tasks related to analyzing and segmenting images. The fundamental concept behind these AI approaches is to extract image patches used to train algorithms²⁹. Digital pathology is transforming various aspects of pathology, such as diagnostic workflows, telepathology, the integration of AI-driven diagnostic algorithms into routine practice, pathology education, and the generation and management of large-scale data³⁰. AI techniques are increasingly utilized in pathology for a diverse array of tasks involving the analysis and segmentation of images³¹. The digitization of pathology allows pathologists to revolutionize their workflow within a bustling diagnostic laboratory. This includes integrating digital scanners with laboratory IT systems, managing and distributing digital slides to pathology personnel both internally and externally, reviewing slides digitally on-screen instead of through a microscope, and reporting cases in a completely digital environment. The largest pivotal trial of digital pathology in the US has demonstrated that this approach is as effective as conventional microscopy-based diagnosis³². There is an urgent need for AI tools that can enhance the productivity of pathology teams to mitigate a growing global shortage of trained pathologists³³.

Computational pathology aims to improve diagnostic accuracy, enhance patient care, and reduce costs through global collaboration. This aligns with the rapid technological progress driving personalized precision medicine³⁴. The shift from traditional glass slides to digital images has not only improved the traditional diagnostic process but has also led to major changes in how medical insights are produced and shared. Further exploration reveals the concept of remote consultations, a critical capability enabled by digital pathology³⁵.

In detecting cancer micro metastases, pathologists aided by AI showed greater accuracy compared to either AI operating alone or pathologists working independently³⁶. Researchers find it crucial to receive diagnostic reports that follow standardized guidelines, detailing specimen type, site, histologic type, grading, and staging. These guidelines are set by the American Joint Committee on Cancer, which organizes various categories of histopathological information using fuzzy ontology principles³⁷.

AI In Clinical Pharmacy:

Clinical pharmacy encompasses the practice of hospital or community pharmacists delivering patient care to optimize medication therapy and promote health, wellness, and disease prevention³⁸. By analyzing a patient's medical history alongside extensive medical literature and clinical trial data, Watson recommends therapies that are potentially most effective for specific types of cancer³⁹.

The swift advancement of AI technology offers a chance to apply it in clinical practice, potentially transforming healthcare services. It is crucial to record and share information about AI's role in clinical practice to educate healthcare providers and provide them with the necessary knowledge and tools for successful integration into patient care⁴⁰. Clinical pharmacy services include direct and indirect patient care. Pharmacists now provide a variety of clinical services globally, such as managing minor ailments, comprehensive medication management (CMM), and independent medication prescribing⁴¹. Under collaborative practice agreements, clinical pharmacists can prescribe and administer medications, perform physical assessments, and order lab or radiology tests. The SSCP advocates for broadening clinical pharmacy services to encompass hospices, long-term care facilities, home healthcare settings, rural areas, and correctional institutions⁴². Clinical pharmacy has shown beneficial results impact the optimization of therapeutic care through activities such as reviewing prescriptions and reconciling medications⁴³. Numerous studies have addressed the clinical and economic impact of clinical pharmacy, demonstrating its value by improving both clinical and economical outcomes⁴⁴. Clinical pharmacy interventions during hospital stays can decrease drug-related harm and improve patient care. The clinical pharmacy service actively enhances patient safety, optimizes drug therapy outcomes, identifies and prevents adverse drug events (ADEs), and boosts the quality, safety, and efficiency of patient care⁴⁵. In the study "Clinical Pharmacy Services and Hospital Mortality Rates" (published in Pharmacotherapy), researchers found that the implementation of certain clinical pharmacy services (including clinical research, drug information, admission drug histories, and pharmacist involvement in the cardiopulmonary resuscitation team) was linked to a notable decrease in mortality rates. This association remained significant even after accounting for disease severity in their analysis⁴⁶.

AI In Regulatory Affairs:

Global pharmaceutical companies establish regulatory affairs departments to ensure the safety, quality, and effectiveness of their drug products, thereby protecting the health and well-being of patients and consumers⁴⁷.

The growing participation of patients in all phases of drug development, including regulatory review, has also influenced the regulation of medicinal products⁴⁸. Artificial intelligence is utilized to analyze safety reports, clinical trial data, and regulatory information. This allows for the assessment of risks associated with new drugs and technologies, as well as the identification of trends and patterns. These insights help evaluate product efficacy and patient safety, ensuring compliance with pharmaceutical regulations. Implementing AI in this manner can also mitigate the risk of costly fines and penalties for pharmaceutical companies⁴⁹.

Artificial intelligence can streamline pharmaceutical regulatory affairs by automating tasks such as administrative work, dossier preparation, data extraction, auditing, regulatory compliance, and quality management⁵⁰. AI can utilize existing data to make accurate predictions about the effectiveness and safety of new compounds. This accelerates the drug discovery process and reduces the frequency of failed experiments, resulting in significant time and cost savings⁵¹. The Regulatory Affairs profession ensures compliance with changing legislation across the geographic areas where the company intends to distribute its products, they provide guidance on legal and technical requirements, evaluate scientific data for research and development, prepare and submit regulatory documents, and manage negotiations to maintain marketing authorization for products⁵².

Figure: 2 Scope of Regulatory Affairs

CONCLUSION:

The document explores the pervasive impact of Artificial Intelligence (AI) in the healthcare and pharmaceutical sectors, emphasizing its influence on clinical decision-making, disease diagnosis, drug discovery, and pharmacy practice. AI technologies such as machine learning (ML), deep learning (DL), and natural language processing (NLP) are widely applied across tasks spanning drug screening and design to personalized medicine and pharmacovigilance.

In drug discovery, AI expedites the identification of potential drug candidates via virtual screening and in silico drug design, thereby mitigating the costs and time typically associated with conventional methodologies. The AlphaFold2 system exemplifies AI's proficiency in accurately predicting protein structures, which is essential for comprehending disease mechanisms and drug interactions.

In pharmacy practice, AI enhances clinical decision support systems, automates medication dispensing, optimizes inventory management, and detects adverse drug reactions (ADR), thereby enhancing patient safety and optimizing healthcare delivery. Although still in its nascent stages, the integration of AI in pharmacy holds promise for significant advancements in personalized medicine and patient care.

Overall, AI's capacity to analyze extensive biomedical datasets and discern patterns presents new opportunities and challenges across pharmaceutical sciences and industries, revolutionizing medical technology and enhancing patient outcomes.

REFERENCES:

1. Sonam Tiwari, Dr. Arun Patel, A review on drug discovery and development: Associated with artificial intelligence. EPRA International Journal of Research and Development (IJRD). 2024; 9(1):141-147

2. Raza MA, Aziz S, Noreen M, et al. Artificial Intelligence (AI) in Pharmacy: An Overview of Innovations. Innov Pharm. 2022; 13(2): 10.24926/iip. V13i2.4839. Published 2022 Dec 12. Doi:10.24926/iip. V13i2.4839

3. Bhattamisra SK, Banerjee P, Gupta P, Mayuren J, Patra S, Candasamy M. Artificial Intelligence in Pharmaceutical and Healthcare Research. Big Data and Cognitive Computing. 2023; 7(1):10. Https://doi.org/10.3390/bdcc7010010

4. Bhattamisra SK, Banerjee P, Gupta P, Mayuren J, Patra S, Candasamy M. Artificial Intelligence in Pharmaceutical and Healthcare Research. Big Data and Cognitive Computing. 2023; 7(1): 10. Https://doi.org/10.3390/bdcc7010010

5. Chalasani SH, Syed J, Ramesh M, Patil V, Pramod Kumar TM. Artificial intelligence in the field of pharmacy practice: A literature review. Explor Res Clin Soc Pharm. 2023 Oct 21; 12: 100346. Doi: 10.1016/j.rcsop.2023.100346. PMID: 37885437; PMCID: PMC10598710.

6. Lu, M. Et al. Artificial Intelligence in pharmaceutical sciences. Engineering. 2023; 27: 37–69. Doi: 10.1016/j.eng.2023.01.014.

7. Sharma, M. Et al. Review on Artificial Intelligence in Medicine. Journal of Young Pharmacists. 2023; 15(1): 1–6. Doi:10.5530/097515050514.

8. Sarda, Rahul, Rachappa Mahale, and Sanjay Motipwar. Artificial Intelligence Importance and application in Pharma Industry.

9. Ganesh Parkhe, Trupti Thange. A Review: Artificial intelligence in drug discovery and development. International Journal of Research Publication and Reviews. 2022; 3(7): 501-510

10. Sonam Tiwari, Arun Patel. A review on drug discovery and development associated with artificial intelligence. International Journal of Research and Development (IJRD). 2024; 9(1).

11. Raza MA, Aziz S. Transformative potential of Artificial Intelligence in pharmacy practice. Saudi Pharm J. 2023; 31(9): 101706. Doi: 10.1016/j.jsps.2023.101706

12. Chalasani SH, Syed J, Ramesh M, Patil V, Pramod Kumar TM. Artificial intelligence in the field of pharmacy practice: A literature review. Explor Res Clin Soc Pharm. 2023; 12: 100346. Published 2023 Oct 21. Doi: 10.1016/j.rcsop.2023.100346

13. Chalasani SH, Syed J, Ramesh M, Patil V, Pramod Kumar TM. Artificial intelligence in the field of pharmacy practice: A literature review. Explor Res Clin Soc Pharm. 2023; 12:100346. Published 2023 Oct 21. Doi: 10.1016/j.rcsop.2023.100346

14. Al Meslamani, A. Z. Applications of AI in pharmacy practice: a look at hospital and community settings. Journal of Medical Economics. 2023; 26(1): 1081–1084. Https://doi.org/10.1080/13696998.2023.2249758

15. Fakeye TO, Adisa R, Olukotun RT, Morawo PK. Hospital and community pharmacists' perception of the scope, barriers and challenges of pharmacy practice-based research in Nigeria. Pharmacy Practice (Granada). 2017 Mar; 15(1).

16. Ma C, Smith HW, Chu C, Juarez DT. Big data in pharmacy practice: current use, challenges, and the future. Integrated Pharmacy Research and Practice. 2015 Aug 6: 91-9.

17. Neill KK, Johnson JT. An advanced pharmacy practice experience in application of evidence-based policy. Am J Pharm Educ. 2012; 76(7): 133. Doi:10.5688/ajpe767133

18. Pandey V, Fozia Khanum A, Singhal M, Sethiya NK, Kumar B. Revolutionizing drug safety: the role of ai in pharmacovigilance.

19. Bates DW, Levine D, Syrowatka A, et al. The potential of artificial intelligence to improve patient safety: a scoping review. NPJ Digit Med. 2021; 4(1): 54. Published 2021 Mar 19. Doi:10.1038/s41746-021-00423-6

20. Murali K, Kaur S, Prakash A, Medhi B. Artificial intelligence in pharmacovigilance: Practical utility. Indian J Pharmacol. 2019; 51(6): 373-376. Doi: 10.4103/ijp.IJP_814_19

21. Poalelungi DG, Musat CL, Fulga A, et al. Advancing Patient Care: How Artificial Intelligence Is Transforming Healthcare. J Pers Med. 2023; 13(8): 1214. Published 2023 Jul 31. Doi:10.3390/jpm13081214

22. Poalelungi DG, Musat CL, Fulga A, et al. Advancing Patient Care: How Artificial Intelligence Is Transforming Healthcare. J Pers Med. 2023; 13(8): 1214. Published 2023 Jul 31. Doi:10.3390/jpm13081214

23. Shen, J., Zhang, C. J. P., Jiang, B., Chen, J., Song, J., Liu, Z., He, Z., Wong, S. Y., Fang, P., and Ming, W. Artificial intelligence versus Clinicians in Disease Diagnosis: Systematic review. JMIR Medical Informatics. 2019; 7(3): e10010. Https://doi.org/10.2196/10010

24. Johnson KB, Wei WQ, Weeraratne D, et al. Precision Medicine, AI, and the Future of Personalized Health Care. Clin Transl Sci. 2021; 14(1): 86-93. Doi:10.1111/cts.12884

25. Johnson, K.B. et al. Precision Medicine, AI, and the future of Personalized Health Care. Clinical and Translational Science. 2020a; 14(1): 86–93. Doi:10.1111/cts.12884.

26. Parekh, Ad-Duhaa E. Mbbsa; Shaikh, Omer A. Mbbsb; Simran, mbbsc; Manan, Sadia mbbsb; Hasibuzzaman, Md. Al mdd . Artificial intelligence (AI) in personalized medicine: AI-generated personalized therapy regimens based on genetic and medical history: short communication. Annals of Medicine and Surgery. 2023; 85(11): 5831-5833 DOI: 10.1097/MS9.0000000000001320

27. Poalelungi DG, Musat CL, Fulga A, et al. Advancing Patient Care: How Artificial Intelligence Is Transforming Healthcare. J Pers Med. 2023; 13(8): 1214. Published 2023 Jul 31. Doi:10.3390/jpm13081214

28. Poalelungi DG, Musat CL, Fulga A, et al. Advancing Patient Care: How Artificial Intelligence Is Transforming Healthcare. J Pers Med. 2023; 13(8): 1214. Published 2023 Jul 31. Doi:10.3390/jpm13081214

29. Shafi S, Parwani AV. Artificial intelligence in diagnostic pathology. Diagnpathol. 2023; 18(1): 109. Published 2023 Oct 3. Doi:10.1186/s13000-023-01375-z

30. Go, Heounjeong. Digital pathology and artificial intelligence applications in pathology. Brain Tumor Research And Treatment. 2022; 10(2): 76-82.

31. Shafi, Saba, and Anil V. Parwani. Artificial intelligence in diagnostic pathology. Diagnostic Pathology. 2323; 18(1): 109.

32. Serag, Ahmed, et al. Translational AI and deep learning in diagnostic pathology. Frontiers in Medicine. 2019; 6: 185.

33. Steiner, David F., Po-Hsuan Cameron Chen, and Craig H. Mermel. Closing the translation gap: AI applications in digital pathology. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1875. 2021; 1: 188452.

34. Cui, Miao, and David Y. Zhang. Artificial intelligence and computational pathology. Laboratory Investigation. 2021; 101(4): 412-422.

35. Kiran N, Sapna F, Kiran F, et al. Digital Pathology: Transforming Diagnosis in the Digital Age. Cureus. 2023; 15(9): e44620. Published 2023 Sep 3. Doi:10.7759/cureus.44620

36. Huo, Yuankai, Ruining Deng, Quan Liu, Agnes B. Fogo, and Haichun Yang. AI applications in renal pathology. Kidney International. 2021; 99(6): 1309-1320.

37. Wong ANN, He Z, Leung KL, To CCK, Wong CY, Wong SCC, Yoo JS, Chan CKR, Chan AZ, Lacambra MD, et al. Current Developments of Artificial Intelligence in Digital Pathology and Its Future Clinical Applications in Gastrointestinal Cancers. Cancers. 2022; 14(15): 3780. Https://doi.org/10.3390/cancers14153780

38. Ranchon, Florence, Sébastien Chanoine, Sophie Lambert-Lacroix, Jean-Luc Bosson, Alexandre Moreau-Gaudry, and Pierrick Bedouch. Development of artificial intelligence powered apps and tools for clinical pharmacy services: A systematic review. International Journal of Medical Informatics. 2023; 172: 104983.

39. Al Meslamani, A. Z. Applications of AI in pharmacy practice: a look at hospital and community settings. Journal of Medical Economics. 2023; 26(1): 1081-1084.

40. Alowais, S.A., Alghamdi, S.S., Alsuhebany, N., Alqahtani, T., Alshaya, A.I., Almohareb, S.N., Aldairem, A., Alrashed, M., Bin Saleh, K., Badreldin, H.A. and Al Yami, M.S. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Medical Education. 2023; 23(1): 689.

41. Mertens, Josephine F., Ellen S. Koster, Vera HM Deneer, Marcel L. Bouvy, and Teun van Gelder. Clinical reasoning by pharmacists: a scoping review. Currents in Pharmacy Teaching and Learning. 2022; 14(10): 1326-1336.

42. Korayem, Ghazwa B., Hisham A. Badreldin, Khalid Eljaaly, Ahmed Aldemerdash, Lujain K. Al-Suhaibani, Hala Joharji, ohoudaljuhani et al. Clinical pharmacy definition, required education, training and practice in Saudi Arabia: A position statement by the Saudi society of clinical pharmacy. Saudi Pharmaceutical Journal. 2021; 29(11): 1343-1347.

43. Hoegy, Delphine, Julie Martin, Marine Barral, Florence Ranchon, Audrey Janoly-Dumenil, Evariste Delande, Christine Pivot et al. Development of clinical pharmacy programs integrated into patient care pathways using adverse event risks. Research in Social and Administrative Pharmacy. 2022; 18(6): 3052-3057.

44. Somers, A., Robays, H., De Paepe, P., Van Maele, G., Perehudoff, K., and Petrovic, M. Evaluation of clinical pharmacist recommendations in the geriatric ward of a Belgian university hospital. Clinical Interventions in Aging. 2023; 8: 703–709. Https://doi.org/10.2147/CIA.S42162

45. Botelho, Stephanie Ferreira, Laís Lessa Neiva Pantuzza, Claudyane Pinheiro Marinho, and Adriano Max Moreira Reis. Prognostic prediction models and clinical tools based on consensus to support patient prioritization for clinical pharmacy services in hospitals: A scoping review. Research in Social and Administrative Pharmacy. 2021; 17(4): 653-663

46. Scheife, R.T. Clinical pharmacy: Just what the patient ordered. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 1999; 19(5): 555–555. Doi:10.1592/phco.19.8.555.31532.

47. Mayer M, Canedo A, Dinh T, Low M, Ortiz A, Garay C. Potential Use of Artificial Intelligence for Regulatory Intelligence: Biopharmaceutical Industry's Views. Ther innovregul Sci. 2019 Nov; 53(6): 759-766. Doi: 10.1177/2168479018812778. Epub 2018 Dec 6. PMID: 30522348.

48. Chisholm, Orin, and Helen Critchley. Future directions in regulatory affairs. Frontiers in Medicine. 2023;9: 1082384.

49. Shelar, Shubhangi, Snehal Bagdane, and Pournima Joshi. Drug regulatory affairs: The potential for machine learning and artificial intelligence.

50. Patil RS, Kulkarni SB, Gaikwad VL. Artificial intelligence in pharmaceutical regulatory affairs. Drug Discov Today. 2023 Sep; 28(9): 103700. Doi: 10.1016/j.drudis.2023.103700. Epub 2023 Jul 12. PMID: 37442291.

51. Shaki F, Amilrkhanloo M, Jahani D, Milad Chahardori M. Artificial Intelligence in Pharmaceuticals: Exploring Applications and Legal Challenges. Pharmaceutical and Biomedical Research. 2024; 10(1): 1-10.

52. Paricharak S, Baravkar A, Masal A, Chougule S, Deshmane P, Kulkarni S. A comprehensive synopsis on cognizance of Regulatory Affairs in different sectors of Pharmacy. Int J Drug Reg Affairs. 2021 ; 9(4): 20-32

Received on 05.11.2024 Revised on 30.11.2024

Accepted on 18.12.2024 Published on 24.02.2025

Available online from February 27, 2025

Asian J. Research Chem.2025; 18(1):31-36.

DOI: 10.52711/0974-4150.2025.00006

This work is licensed under a Creative Commons Attribution-Non-Commercial-Share Alike 4.0 International License. Creative Commons License.